Oppenheimer & Co. Inc. lowered its position in shares of Rockwell Medical, Inc. (NASDAQ:RMTI) by 4.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,300 shares of the company’s stock after selling 1,000 shares during the period. Oppenheimer & Co. Inc.’s holdings in Rockwell Medical were worth $153,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Cutter & CO Brokerage Inc. boosted its position in Rockwell Medical by 6.3% during the 2nd quarter. Cutter & CO Brokerage Inc. now owns 25,325 shares of the company’s stock valued at $201,000 after buying an additional 1,500 shares during the period. Balasa Dinverno & Foltz LLC raised its holdings in Rockwell Medical by 5.8% in the 2nd quarter. Balasa Dinverno & Foltz LLC now owns 54,300 shares of the company’s stock worth $431,000 after purchasing an additional 3,000 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its holdings in Rockwell Medical by 11.3% in the 1st quarter. Metropolitan Life Insurance Co. NY now owns 42,220 shares of the company’s stock worth $264,000 after purchasing an additional 4,287 shares in the last quarter. KCG Holdings Inc. bought a new position in Rockwell Medical in the 1st quarter worth $111,000. Finally, Geode Capital Management LLC raised its holdings in Rockwell Medical by 9.7% in the 1st quarter. Geode Capital Management LLC now owns 371,700 shares of the company’s stock worth $2,326,000 after purchasing an additional 32,964 shares in the last quarter. 21.36% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Oppenheimer & Co. Inc. Has $153,000 Holdings in Rockwell Medical, Inc. (RMTI)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/23/oppenheimer-co-inc-has-153000-holdings-in-rockwell-medical-inc-rmti.html.

Several research analysts have commented on the stock. Zacks Investment Research lowered shares of Rockwell Medical from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th. BidaskClub upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Ifs Securities assumed coverage on shares of Rockwell Medical in a report on Monday, August 14th. They issued a “strong-buy” rating and a $11.00 price objective for the company. Finally, ValuEngine lowered shares of Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $8.38.

Rockwell Medical, Inc. (NASDAQ RMTI) opened at 7.38 on Friday. The firm has a 50-day moving average of $6.47 and a 200 day moving average of $7.00. The company’s market capitalization is $381.84 million. Rockwell Medical, Inc. has a one year low of $3.55 and a one year high of $8.98.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). The business had revenue of $13.24 million during the quarter, compared to analysts’ expectations of $13.05 million. Rockwell Medical had a negative net margin of 39.68% and a negative return on equity of 42.22%. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.11) EPS. Equities research analysts predict that Rockwell Medical, Inc. will post ($0.44) earnings per share for the current fiscal year.

Rockwell Medical Profile

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Want to see what other hedge funds are holding RMTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rockwell Medical, Inc. (NASDAQ:RMTI).

Institutional Ownership by Quarter for Rockwell Medical (NASDAQ:RMTI)

Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.